Proteomics Market to Expand Rapidly, with 13% CAGR forecast Through 2030
BOSTON, July 25, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Proteomics: Technologies and Global Markets" was valued at $27.6 billion in 2024 and is projected to grow from $31.0 billion in 2025 to $57.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.0% from 2025 to 2030.
The report offers a detailed analysis of the global market for proteomic technologies, segmented by product type (instruments and software, consumables), platform (mass spectrometry, biochip), application (drug discovery and development, research, diagnostics, applied proteomics), and region (North America, Europe, Asia-Pacific, and Rest of the World). Protein structural analysis and protein-expression products are outside the scope of the report. The study discusses market trends, challenges, and emerging technologies, while also examining the competitive landscape and the market shares of leading vendors. It includes a section on ESG trends and provides company profiles that include insights into financials, product portfolios, and recent advances. This analysis serves as a valuable resource for understanding strategic opportunities and market dynamics in the evolving proteomics sector.
This report is particularly relevant today due to the growing demand for innovative and personalized therapies, which is driving advances in proteomic technologies. Increased investments in R&D are accelerating the discovery of new biomarkers, which are crucial for early and accurate diagnosis of diseases. These trends underscore the importance of proteomics in shaping the future of precision medicine and improving healthcare outcomes.
The factors driving the market's growth include:
Increasing Investments in R&D: Governments, biotech firms, and academic institutions are increasing funding in proteomics research to drive innovation in diagnostics, drug discovery, and therapeutic development.
Transition Towards Personalized Medicine: Proteomics enables the identification of protein biomarkers that support tailored treatments based on individual biological profiles, making it a cornerstone in the shift toward personalized healthcare.
Aging Population and Prevalence of Chronic Diseases: As the global population ages, chronic conditions like cancer and cardiovascular diseases are becoming more common, increasing the demand for proteomics tools that aid in early detection and targeted treatment.
Emerging Technologies: Advances such as high-resolution mass spectrometry, AI-driven data analysis, and single-cell proteomics are accelerating research making it more precise, and cost-effective, thereby expanding the scope and impact of proteomics.
Request a sample copy of the global market for proteomic technologies report.
Report Synopsis
Report Metric
Details
Base year considered
2024
Forecast period considered
2025-2030
Base year market size
$27.6 billion
Market size forecast
$57.2 billion
Growth rate
CAGR of 13.0% from 2025 to 2030
Segments covered
Platform, Application, Product Type and Region
Regions covered
North America, Europe, Asia-Pacific and the Rest of the World (RoW)
Countries covered
U.S., Canada, Mexico, Germany, the U.K., Italy, France, Spain, Japan, China, India, South Korea, Rest of Asia-Pacific, and Rest of Europe
Market drivers
Increasing investments in R&D.
Transition towards personalized medicine.
Aging population and growing prevalence of chronic diseases.
Emerging technologies.
Interesting facts:
Advances in Technology: The market has seen notable progress in mass spectrometry, particularly with improvements in software and automation that streamline essential processes like sample preparation.
Innovation from Emerging Companies: Start-up companies such as Nautilus and SomaLogic have introduced innovative platforms that are expected to reshape the market's future.
Emerging startup:
Alamar Biosciences
Nautilus Biotechnology
Pixelgen Technologies
Syncell Inc.
Sengenics
The report addresses the following questions:
What is the projected size and growth rate of the market?- The global proteomics market was valued at $27.6 billion in 2024 and is expected to grow at a CAGR of 13% to reach $57.2 billion by the end of 2030.
Which factors are driving the growth of the market?- The global market of proteomic technologies is growing due to the rising aging population and growing prevalence of chronic diseases, increasing investments in R&D and in the biotechnology sector, and rising demand for personalized medicine.
Which market segments are covered in the report?- The global market for proteomic technologies is segmented based on platform, product type, application, and region.
Which platform type will be dominant through 2030?- The mass spectrometry segment will be dominant through 2030.
Which region has the largest market share?- North America holds the largest share of the market.
Market Leaders include:
AGILENT TECHNOLOGIES INC.
ARRAYIT CORP.
BIO-RAD LABORATORIES INC.
BIO-TECHNE
BRUKER
CREATIVE PROTEOMICS
DANAHER CORP.
JEOL LTD.
MERCK KGAA
PROMEGA CORP.
REVVITY
SHIMADZU CORP.
STANDARD BIOTOOLS
THERMO FISHER SCIENTIFIC INC.
WATERS CORP.
Related reports:
Single-Cell Genomics and Proteomics: Emerging Technologies and Markets: This report reviews the single-cell genomics and proteomics market, highlighting its current landscape and future potential. It examines key market drivers, challenges, and opportunities, and segments the market by product type (genomics, epigenomics, transcriptomics), application areas (oncology and immunology), end users (academic institutions and biotech companies), and regions (North America, Europe, Asia-Pacific, and the Rest of the World). It also includes profiles of major companies, covering their business segments, financials, product offerings, and recent developments.
Global Multiomics Market: This report provides a detailed analysis of the global multiomics market, focusing on products, platforms, applications, end-users, and regions. It explores market trends and forecasts, along with insights into major players and geographic opportunities. The report also includes strategic tools like PESTEL and ESG analysis, competitive assessments, and recommendations to help companies plan effectively.
Purchase a copy of the report direct from BCC Research.
For further information on any of these reports or to make a purchase, contact info@bccresearch.com.
About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
Contact Us
Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@bccresearch.comPhone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo - https://mma.prnewswire.com/media/2183242/5431771/BCC_Research_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/proteomics-market-to-expand-rapidly-with-13-cagr-forecast-through-2030-302514076.html
SOURCE BCC Research LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Birch Hill and Brookfield to acquire First National Financial for $2.9 billion
(Reuters) -First National Financial said on Sunday that it has reached an agreement to be acquired by Birch Hill Equity partners and asset manager Brookfield Asset Management in a deal valuing the company's equity at $2.9 billion. Sign in to access your portfolio
Yahoo
9 minutes ago
- Yahoo
A More Affordable EV Won't Save Tesla
Key Points Tesla fell 5% after hours on its second-quarter earnings report. Some investors saw production of a new, more affordable vehicle as a positive sign. The company launched its robotaxi network in June. These 10 stocks could mint the next wave of millionaires › Tesla (NASDAQ: TSLA) issued another disappointing earnings report on Tuesday. Switch Auto Insurance and Save Today! Affordable Auto Insurance, Customized for You The Insurance Savings You Expect Great Rates and Award-Winning Service The leading electric vehicle (EV) maker finished the after-hours session down 5%, but the sell-off could have been worse. The company reported a decline in both sales and profit. Revenue was down 12% to $22.5 billion, and adjusted net income was down 23% to $1.39 billion, or $0.40 per share. Those numbers actually topped a muted revenue estimate at $22.13 billion, while the bottom-line consensus matched the results at $0.40. Tesla's problems have been well-documented at this point. CEO Elon Musk's turn in the political spotlight seemed to backfire after his relationship with President Donald Trump went sour. Due in part to Musk's involvement with politics, the brand has become unappealing in the eyes of some potential buyers, leading to a 16% decline in automotive revenue. Sales have plunged in Europe, and the company is losing ground to more affordable Chinese EVs. One seemingly bright spot Musk has a long history of overcoming weak results by telling investors what they want to hear on the earnings call, including making big promises about its robotaxi network and other initiatives in autonomy like its Optimus robot. He seemed to do that again on the latest earnings call, with some comments about the more affordable model he has long promised, which some have dubbed the Tesla Model 2. Musk said that the company started production of the vehicle in June and is ramping up production now. He added: "The goal with those products was not to negatively impact revenue or gross margin, but just to make a car that everyone loves and wants at a more affordable price." Musk has long argued that price competition was one of the biggest headwinds facing the company, but the brand crisis seems to have overshadowed that. By introducing its own lower-priced model, Tesla may end up cannibalizing its more expensive vehicles. Customers may be choosing between a more expensive Tesla and that lower-priced model, rather than another brand. The new vehicle is just a cheaper Model Y, rather than a brand-new vehicle model. The robotaxi initiative The biggest reason Tesla has maintained its premium valuation even as sales and profits have tumbled is that investors believe that Tesla's robotaxi network could go mainstream, fulfilling Musk's long-term vision. However, the robotaxi has gotten off to only a modest start after launching in June, and it seemed to get less attention on Tuesday's earnings call, though Musk reminded the audience: "As you can tell, autonomy is the story." Management said that robotaxis in Austin, Texas have topped 7,000 miles with no significant safety interventions. The company is aiming to launch the robotaxi in the San Francisco Bay Area next. Tesla needs growth in its core business Investors have bid up Tesla stock on hopes for its initiatives in robotaxis and more affordable vehicles, but the company needs to return to growth in selling EVs for the stock to be successful over the long term. The decline in EV sales is a reflection of a backlash against Tesla's brand. The company is also expected to struggle over the next few quarters due to the elimination of the EV tax credit and a change in other federal policies that supported EV adoption. The company also faces a $300 million effect from tariffs. Tesla could get back on track, especially if the robotaxi network takes off. But the current valuation in the stock leaves little room for upside if it does, especially given the persistent challenges in EV sales. While a more affordable vehicle might be a step in the right direction, it seems more likely to undercut demand for Tesla's more expensive vehicles, rather than competing with alternatives. Should you buy stock in Tesla right now? The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Jeremy Bowman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy. A More Affordable EV Won't Save Tesla was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Android Authority
10 minutes ago
- Android Authority
Google says it's working to fix voice commands for your smart lights
Lil Katz / Android Authority TL;DR Google has acknowledged a bug affecting voice commands for smart lights. The company says it is aware of the issue and will share an update soon. Many users say they can still control lights via the Google Home app, but not through Assistant voice commands. Google has confirmed it's investigating a bug preventing users from controlling their smart lights through Google Assistant voice commands. We first reported on the issue over the weekend, as user complaints have continued to pile up on Reddit and Google's support forums in recent days. Android Authority's Rita El Khoury also experienced the problem firsthand, noting that her Nest Audio speaker stopped responding to voice commands to turn off the lights. In a comment posted on Reddit, the official Google Nest account has now addressed the problem: We're aware of an issue with using voice commands to control some lights. We'll share an update as soon as possible, thanks for your patience. While Google hasn't provided a timeline for a fix, it's clear the issue is more than a small glitch. Affected users report various problems, including Google not recognizing light groups, turning off the wrong lights, or responding with silence when given commands like 'Hey Google, turn off the lights.' Most users say the lights can still be controlled via the Google Home app, suggesting that the issue lies specifically with Assistant voice functionality. Some users have found workarounds, such as syncing devices again or removing and re-adding their lighting services, but results vary. 'I had this problem too. I saw someone else post a fix earlier today (Google must have done something that messed things up). You just need to reconnect the service you use for your lights. Go to Google Home app, click the + button to add a new device. Go to the works with Google section and reconnect any of the services you use for the lights. That should work… Maybe,' a user noted on Reddit. However, this may not be an easy fix for those who have multiple lights connected throughout their home. The bug comes at a difficult time for Google's smart home ecosystem, which has been under increased scrutiny from users citing reliability issues. Google has also promised major improvements to the platform in the fall. Until then, users will have to wait for an official fix for this particular problem related to voice commands for connected lights or rely on manual controls as a workaround.
